^
Association details:
| Biomarker: | EGFR exon 19 deletion + TP53 mutation + RB1 mutation |
|---|---|
| Cancer: | Small Cell Lung Cancer |
| Drug: | gefitinib (EGFR inhibitor) + Focus V (anlotinib) (Multi-tyrosine kinase inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Case Report: Re-Sensitization to Gefitinib in Lung Adenocarcinoma Harboring EGFR Mutation and High PD-L1 Expression After Immunotherapy Resistance, Which Finally Transform Into Small Cell Carcinoma
Published date:
06/24/2021
Excerpt:
A 43-year-old male Asian non-smoker underwent surgical resection of lung mass...Bronchoscopy was performed and repeated biopsy showed the left lung mass transformed into SCLC...trunk gene mutations as EGFR 19-del mutation, TP53 and RB1 mutation...The patient sequentially received etoposide and cisplatin, anlotinib plus gefitinib...Finally, he died after one cycle of etoposide and carboplatin plus durvalumab treatment in March 2020.
Secondary therapy:
cisplatin + etoposide IV
DOI:
10.3389/fonc.2021.661034
